PLoS ONE (Jan 2023)

A longitudinal multidimensional rehabilitation program for patients undergoing allogeneic blood and marrow transplantation (CaRE-4-alloBMT): Protocol for a phase II feasibility pilot randomized controlled trial.

  • Samantha Tam,
  • Rajat Kumar,
  • Paty Lopez,
  • Jonas Mattsson,
  • Shabbir Alibhai,
  • Eshetu G Atenafu,
  • Lori J Bernstein,
  • Eugene Chang,
  • Susan Clarke,
  • David Langelier,
  • Jeffrey Lipton,
  • Samantha Mayo,
  • Tina Papadakos,
  • Jennifer Michelle Jones

DOI
https://doi.org/10.1371/journal.pone.0285420
Journal volume & issue
Vol. 18, no. 5
p. e0285420

Abstract

Read online

BackgroundAllogeneic blood and marrow transplantation (alloBMT) is a curative treatment for blood cancers associated with various treatment-related adverse events and morbidities. Current rehabilitation programs are limited for patients undergoing alloBMT and research is urgently needed to test the acceptability and effectiveness of these programs. In response, we developed a 6-month multidimensional longitudinal rehabilitation program that spans from pre transplant to 3 months post transplant discharge (CaRE-4-alloBMT).MethodsThis study is a phase II randomized controlled trial (RCT) conducted at the Princess Margaret Cancer Centre in patients undergoing alloBMT. A total of 80 patients stratified by frailty score will be randomized to receive usual care (n = 40) or CaRE-4-alloBMT plus usual care (n = 40). The CaRE-4-alloBMT program includes individualized exercise prescriptions, access to online education through a dedicated self-management platform, wearable technology for remote monitoring, and remote tailored clinical support. Feasibility will be assessed by examining the recruitment and retention rates and adherence to the intervention. Safety events will be monitored. Acceptability of the intervention will be assessed through qualitative interviews. Secondary clinical outcomes will be collected through questionnaires and physiological assessments at baseline (T0, 2-6 weeks pre-transplant), transplant hospital admission (T1), hospital discharge (T2), and 3 months post-discharge (T3).ConclusionThis pilot RCT study will determine the feasibility and acceptability of the intervention and study design and will inform full-scale RCT planning.